Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AURORA 2: Long-term Safety and Efficacy of Orelvo (voclosporin) in Lupus Nephritis
2016-004046-28Phase 3Active
- Sponsor
- Aurinia Pharmaceuticals, Inc.
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in lupus nephritis (LN) comparing Orelvo (voclosporin) with Placebo (2 arms). Primary endpoint: Adverse events and laboratory safety profile. Started Jan 2018; status: active.
02
Drugs
voclosporin
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on 2016-004046-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004046-28.